Cocrystal pharma's covid-19 oral and intranasal/pulmonary protease inhibitors exhibit powerful in vitro potency against the sars-cov-2 omicron variant

Antiviral activity now confirmed against sars-cov-2 and all variants of concern including omicron, delta, alpha, beta and gamma

COCP Ratings Summary

COCP Quant Ranking